Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting MAGE-A4 in Multiple Solid Tumors
May 16 2017 - 7:59AM
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell
therapy to treat cancer, today announced that it has initiated the
first site for its MAGE‑A4 SPEAR T-cell study in patients with
multiple malignant solid tumors. This study is now open for
enrollment.
This is Adaptimmune’s third wholly-owned therapeutic candidate
to enter clinical trials. The Company already has ongoing studies
to evaluate its T-cell therapies targeting the MAGE-A10 cancer
antigen in patients with non-small cell lung cancer, urothelial
cancer, melanoma, or head and neck cancers; and AFP in
patients with hepatocellular carcinoma.
“We are excited to initiate this study to evaluate our MAGE-A4
T-cell therapeutic candidate in patients with multiple malignant
solid tumors,” said Rafael Amado, Adaptimmune’s Chief Medical
Officer. “Preclinical evaluations of our MAGE-A4 affinity matured
T-cell receptor show optimized targeting of, and specificity for,
MAGE-A4 expressing cancer cells. MAGE-A4 is among the most commonly
expressed cancer embryonic antigens; therefore, we have the
opportunity to evaluate the potential of this promising therapy in
a wide range of cancers.”
This is a Phase I, open label, dose escalation study designed to
evaluate the safety and anti-tumor activity of Adaptimmune’s
MAGE-A4 therapeutic candidate in patients who are HLA-A*02 positive
and have inoperable locally advanced or metastatic melanoma,
urothelial, head and neck, ovarian, non-small cell lung,
esophageal, and gastric cancers expressing MAGE-A4. The study will
enroll up to 32 patients. The primary objective of the study is to
evaluate the safety and tolerability of MAGE-A4 SPEAR T-cell
therapy. Additional objectives include anti‑tumor activity,
persistence of genetically modified cells in the body, and
evaluation of the phenotype and functionality of genetically
modified cells isolated from peripheral blood or tumor post
infusion.
Additional information about this study is available at
www.clinicaltrials.gov by searching on NCT03132922.
About AdaptimmuneAdaptimmune is a
clinical-stage biopharmaceutical company focused on the development
of novel cancer immunotherapy products. The Company’s unique SPEAR
(Specific Peptide Enhanced Affinity Receptor) T-cell platform
enables the engineering of T-cells to target and destroy cancer,
including solid tumors. Adaptimmune has a number of proprietary
clinical programs, and is also developing its NY-ESO SPEAR T-cell
program under a strategic collaboration and licensing agreement
with GlaxoSmithKline. The Company is located in Philadelphia, USA
and Oxfordshire, U.K. For more information, please visit
http://www.adaptimmune.com
Forward-Looking StatementsThis release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995 (PSLRA). These
forward-looking statements involve certain risks and uncertainties.
Such risks and uncertainties could cause our actual results to
differ materially from those indicated by such forward-looking
statements, and include, without limitation: the success, cost and
timing of our product development activities and clinical trials
and our ability to successfully advance our TCR therapeutic
candidates through the regulatory and commercialization processes.
For a further description of the risks and uncertainties that could
cause our actual results to differ materially from those expressed
in these forward-looking statements, as well as risks relating to
our business in general, we refer you to our Quarterly Report on
Form 10-Q filed with the Securities and Exchange Commission (SEC)
on May 10, 2017, and our other SEC filings. The forward-looking
statements contained in this press release speak only as of the
date the statements were made and we do not undertake any
obligation to update such forward-looking statements to reflect
subsequent events or circumstances.
Adaptimmune Contacts Investor Relations
Juli P. Miller, Ph.D. T: (215) 825-9310
E: juli.miller@adaptimmune.com
Media Relations Margaret Henry
T: +44 (0)1235 430036
Cell: +44 (0)7710 304249
E: margaret.henry@adaptimmune.com
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Apr 2023 to Apr 2024